Lytix Biopharma ASA to Showcase Promising Phase II Results for Ruxotemitide Combination Therapy at ASCO 2026
Combination therapy demonstrates potential to drive durable anti-tumor responses in difficult-to-treat cancers
Oslo, Norway, April 21 2026: Lytix Biopharma ASA (“Lytix” or the “Company”), a clinical-stage immuno-oncology company developing novel intratumoral cancer therapies, today announced that aggregate data analysis from its Phase II ATLAS-IT-03 and ATLAS-IT-05 studies evaluating ruxotemitide (LTX-315) in combination with pembrolizumab have been selected for presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting 2026, taking place May 29 – June 2, 2026 in Chicago, Illinois.
The presentation will include data evaluating intratumoral ruxotemitide (LTX-315) in combination with pembrolizumab in patients with unresectable advanced melanoma who have failed to respond to anti-PD-1 or anti-PD-L1 therapies, as well as triple negative breast cancer patients that were immunotherapy naïve.
“We are pleased that the ASCO scientific committee has selected this work for presentation at this year’s meeting,” said Øystein Rekdal, Chief Executive Officer of Lytix Biopharma. “These results further support the potential of ruxotemitide in combination with pembrolizumab to induce durable anti-tumor responses in patients with advanced melanoma and triple negative breast cancer.”
Poster Presentation Details:
Title: Safety and efficacy of intratumoral (IT) ruxotemitide (LTX 315) in combination with pembrolizumab in patients with unresectable advanced melanoma or triple negative breast cancer (TNBC). Session Title: Poster Session - Developmental Therapeutics—Immunotherapy Session Date and Time: May 30, 2026, 1:30 PM-4:30 PM CDT Poster Number: 392
The data will be presented by Prof. Aurélien Marabelle, MD, PhD, of Gustave Roussy, France.
Following the ASCO Annual Meeting, a copy of the poster will be made available on the Company’s website.
About Ruxotemitide (LTX-315) Ruxotemitide (LTX-315) is a first-in-class oncolytic peptide designed for intratumoral administration. The molecule disrupts tumor cells locally, leading to the release of tumor antigens and danger-associated molecular signals that may activate systemic anti-tumor immune responses. This mechanism has the potential to convert immunologically “cold” tumors into “hot” tumors and enhance responses to checkpoint inhibitor therapies.
About Lytix Biopharma Based in Oslo, Norway, Lytix Biopharma is a clinical-stage biotech company with a highly differentiated oncolytic molecule platform based on world-leading research in host-defense peptide-derived molecules. Lytix Biopharma’s lead product, ruxotemitide (formerly LTX-315), is a first-in-class oncolytic molecule representing a new approach to maintaining durable anti-cancer immunity. Lytix Biopharma has a pipeline of molecules that work across multiple cancer indications and treatment settings, both as mono- and combination therapy. Lytix is listed on Euronext Growth Oslo under the ticker LYTIX.